486,984 Shares in Adaptive Biotechnologies Corporation $ADPT Bought by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC bought a new position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 486,984 shares of the company’s stock, valued at approximately $10,446,000. Parkman Healthcare Partners LLC owned about 0.31% of Adaptive Biotechnologies at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in ADPT. BlackRock Inc. acquired a new position in shares of Adaptive Biotechnologies in the second quarter valued at about $324,735,000. Westfield Capital Management Co. LP acquired a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth about $65,942,000. Price T Rowe Associates Inc. MD boosted its position in Adaptive Biotechnologies by 303.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after buying an additional 3,299,635 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after buying an additional 2,731,648 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in Adaptive Biotechnologies by 248.8% in the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after buying an additional 2,216,595 shares during the period. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Insider Activity

In related news, CEO Chad M. Robins sold 278,676 shares of Adaptive Biotechnologies stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $24.48, for a total value of $6,821,988.48. Following the completion of the transaction, the chief executive officer owned 2,180,518 shares in the company, valued at $53,379,080.64. The trade was a 11.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert Hershberg sold 30,664 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $24.40, for a total value of $748,201.60. Following the completion of the transaction, the director directly owned 46,683 shares of the company’s stock, valued at $1,139,065.20. The trade was a 39.64% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 2,062,325 shares of company stock worth $46,659,069. 5.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ADPT. Guggenheim raised their price target on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. TD Cowen upped their price objective on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Morgan Stanley raised their target price on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. BTIG Research boosted their target price on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Finally, Piper Sandler upped their price target on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $24.42.

Adaptive Biotechnologies Stock Performance

Shares of NASDAQ ADPT opened at $25.55 on Tuesday. The company has a market capitalization of $4.08 billion, a PE ratio of -62.32 and a beta of 2.08. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. The company’s fifty day moving average price is $22.22 and its 200 day moving average price is $17.39. Adaptive Biotechnologies Corporation has a 1 year low of $12.00 and a 1 year high of $26.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). The firm had revenue of $71.55 million during the quarter, compared to analysts’ expectations of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The firm’s quarterly revenue was up 21.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.17) EPS. On average, research analysts predict that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current year.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.